t(4;14) translocations of FGFR3

Stable Identifier
R-HSA-2033515
Type
Pathway
Species
Homo sapiens
Compartment
plasma membrane
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
t(4;14) translocations of FGFR3
Click the image above or here to open this pathway in the Pathway Browser
Translocations which put the FGFR3 gene under the control of the strong IGH promoter have been identified in 15% of multiple myelomas (Avet-Loiseau, 1998; Chesi, 1997; Chesi, 2001). This translocation, which occurs 70kb upstream of the FGFR3 gene, also involves the nearby multiple myeloma SET-domain containing (MMSET) gene (Lauring, 2008), and although the contribution of each of these genes to the development of cancer has not been fully elucidated, several studies have shown that t(4:14) myeloma cell lines are sensitive to FGFR3 inhibitors (Trudel, 2006; Qing, 2009). In ~5% of cases, the translocation is accompanied by activating mutations of FGFR3 (Onwuazor, 2003; Ronchetti, 2001). The t(4;14) translocation results in overexpression of FGFR3 and subsequent ligand independent or anomalous ligand-dependent signaling (Otsuki, 1999).
Literature References
PubMed ID Title Journal Year
9207791 Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

Kuehl, WM, Nardini, E, Chesi, M, Brents, LA, Schröck, E, Bergsagel, PL, Ried, T

Nat Genet 1997
12835230 Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients

Wen, XY, Onwuazor, ON, Masih-Khan, E, Barlogie, B, Zhuang, L, Stewart, AK, Claudio, J, Shaughnessy JD, Jr, Wang, DY

Blood 2003
10568829 Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation

Otsuki, T, Kurebayashi, J, Ueki, A, Sakaguchi, H, Taniwaki, M, Yamada, O, Yata, K, Nakazawa, N, Yawata, Y

Int J Oncol 1999
19381019 Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

Stephan, JP, Dornan, D, Stinson, S, Wiesmann, C, Du, X, Wu, P, Qing, J, Ashkenazi, A, Wu, Y, Tien, J, French, D, Totpal, K, Chan, P, Chen, Y, Marsters, S, Ross, S, Li, H, Wang, QR, Stawicki, S

J Clin Invest 2009
16467200 The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells

Wei, E, Yayon, A, Trudel, S, Rom, E, Chumakov, I, Chang, H, Li, ZH, Stewart, AK, Liang, SB, Singer, Y, Kotzer, S

Blood 2006
11429702 Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations

Otsuki, T, Lombardi, L, Colombo, G, Greco, A, Compasso, S, Neri, A, Ronchetti, D, Dell'Era, P

Oncogene 2001
9865713 High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies

Harousseau, JL, Talmant, P, Li, JY, Avet-Loiseau, H, Jaccard, A, Facon, T, Bataille, R, Rapp, MJ, Morineau, N, Trimoreau, F, Maloisel, F, Brigaudeau, C

Cancer Res 1998
11157491 Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

Mesri, EA, Kuehl, WM, Ely, SA, Chesi, M, Brents, LA, Bergsagel, PL, Bais, C, Robbiani, DF

Blood 2001
17942756 The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity

Abukhdeir, AM, Arceci, RJ, Lauring, J, Park, BH, Matsui, W, Garay, JP, Konishi, H, Wang, Q, Gustin, JP

Blood 2008
Participants
Events
Participates
as an event of
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2012-02-10)
Reviewed
Ezzat, S  (2012-05-15)
Created
Rothfels, K  (2012-01-09)
Cite Us!